{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:24:32Z","timestamp":1789118672852,"version":"build-2803163510"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T00:00:00Z","timestamp":1784851200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Xi\u2019an Health Commission scientific research project","award":["2025ms05"],"award-info":[{"award-number":["2025ms05"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Piperacillin\/tazobactam (TZP) is widely used in hospitalised adults. Real\u2011world data suggest a higher risk of hypokalaemia than previously recognised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To investigate incidence, severity and risk factors of TZP\u2011induced hypokalaemia, and to develop and externally validate a nomogram for individualised risk prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Method<\/jats:title>\n                    <jats:p>This retrospective study included hospitalised adults receiving TZP (2021\u20132025). TZP\u2011induced hypokalaemia was defined as serum potassium &lt;\u20093.5\u00a0mmol\/L\u2009\u2265\u200948\u00a0h after TZP initiation. Logistic regression identified predictors. A nomogram was constructed. Model performance was assessed by discrimination (area under the ROC curve, AUC), calibration (Hosmer\u2011Lemeshow test, calibration intercept\/slope), Brier score and decision\u2011curve analysis (DCA), with internal and external validation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 643 patients, 122 (19.0%) developed TZP\u2011induced hypokalaemia (mild: 78.7%; moderate: 16.4%; severe: 4.9%). Median time to onset was 5.0\u00a0days. Independent predictors were age \u2265\u200965\u00a0years (OR\u2009=\u20092.118, 95% CI 1.003\u20134.472,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.049), body mass index (OR\u2009=\u20090.671, 95% CI 0.591\u20130.762,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), intensive care unit admission (OR\u2009=\u20092.915, 95% CI 1.504\u20135.651,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.002), daily dose (OR\u2009=\u20091.280, 95% CI 1.110\u20131.476,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and baseline serum potassium (OR\u2009=\u20090.123, 95% CI 0.056\u20130.271,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). The nomogram showed good discrimination (training AUC 0.881, internal 0.876, external 0.813), calibration (Hosmer\u2011Lemeshow\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05), Brier scores &lt;\u20090.25 and positive net benefit on DCA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>TZP\u2011induced hypokalaemia is common in hospitalised adults. A nomogram based on five readily available clinical variables may facilitate early identification of high\u2011risk patients, although prospective validation in diverse settings is required before clinical implementation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11096-026-02195-z","type":"journal-article","created":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T12:53:29Z","timestamp":1784897609000},"page":"2105-2116","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Active surveillance and risk prediction of piperacillin\/tazobactam\u2011associated hypokalaemia: development and external validation of a clinical nomogram"],"prefix":"10.1007","volume":"48","author":[{"given":"Hehe","family":"Bai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nanbo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojing","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,24]]},"reference":[{"issue":"4","key":"2195_CR1","doi-asserted-by":"publisher","first-page":"R135","DOI":"10.1530\/ec-18-0109","volume":"7","author":"E Kardalas","year":"2018","unstructured":"Kardalas E, Paschou SA, Anagnostis P, et al. Hypokalemia: a clinical update. Endocr Connect. 2018;7(4):R135\u201346. https:\/\/doi.org\/10.1530\/ec-18-0109.","journal-title":"Endocr Connect"},{"issue":"3","key":"2195_CR2","doi-asserted-by":"publisher","first-page":"111","DOI":"10.4103\/ijcep.ijcep_43_17","volume":"4","author":"UK Udensi","year":"2017","unstructured":"Udensi UK, Tchounwou PB. Potassium homeostasis, oxidative stress, and human disease. Int J Clin Exp Physiol. 2017;4(3):111\u201322. https:\/\/doi.org\/10.4103\/ijcep.ijcep_43_17.","journal-title":"Int J Clin Exp Physiol"},{"issue":"11","key":"2195_CR3","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1093\/eurheartj\/ehm091","volume":"28","author":"A Ahmed","year":"2007","unstructured":"Ahmed A, Zannad F, Love TE, et al. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J. 2007;28(11):1334\u201343. https:\/\/doi.org\/10.1093\/eurheartj\/ehm091.","journal-title":"Eur Heart J"},{"issue":"2","key":"2195_CR4","first-page":"321","volume":"33","author":"AHM Moniruzzaman","year":"2024","unstructured":"Moniruzzaman AHM, Uddin MJ, Battacharjee M, et al. Study of serum electrolytes (sodium and potassium) abnormalities in acute stroke. Mymensingh Med J. 2024;33(2):321\u20136.","journal-title":"Mymensingh Med J"},{"issue":"6","key":"2195_CR5","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1136\/pn-2022-003433","volume":"22","author":"M Rabenstein","year":"2022","unstructured":"Rabenstein M, Abicht A, Brunn A, et al. Persistent hypokalaemia and intermittent muscle weakness. Pract Neurol. 2022;22(6):518\u201320. https:\/\/doi.org\/10.1136\/pn-2022-003433.","journal-title":"Pract Neurol"},{"issue":"1","key":"2195_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijcard.2008.05.047","volume":"137","author":"AB Alper","year":"2009","unstructured":"Alper AB, Campbell RC, Anker SD, et al. A propensity-matched study of low serum potassium and mortality in older adults with chronic heart failure. Int J Cardiol. 2009;137(1):1\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2008.05.047.","journal-title":"Int J Cardiol"},{"issue":"8","key":"2195_CR7","doi-asserted-by":"publisher","first-page":"228","DOI":"10.31083\/j.rcm2408228","volume":"24","author":"BP Huang","year":"2023","unstructured":"Huang BP, Zhao L, Zhao XM, et al. Serum potassium levels and mortality in hospitalized heart failure patients. Rev Cardiovasc Med. 2023;24(8):228. https:\/\/doi.org\/10.31083\/j.rcm2408228.","journal-title":"Rev Cardiovasc Med"},{"issue":"3","key":"2195_CR8","doi-asserted-by":"publisher","first-page":"e0174686","DOI":"10.1371\/journal.pone.0174686","volume":"12","author":"LM Kieneker","year":"2017","unstructured":"Kieneker LM, Eisenga MF, Joosten MM, et al. Plasma potassium, diuretic use and risk of developing chronic kidney disease in a predominantly White population. PLoS ONE. 2017;12(3):e0174686. https:\/\/doi.org\/10.1371\/journal.pone.0174686.","journal-title":"PLoS ONE"},{"issue":"1","key":"2195_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/157488609787354369","volume":"4","author":"C Ben Salem","year":"2009","unstructured":"Ben Salem C, Hmouda H, Bouraoui K. Drug-induced hypokalaemia. Curr Drug Saf. 2009;4(1):55\u201361. https:\/\/doi.org\/10.2174\/157488609787354369.","journal-title":"Curr Drug Saf"},{"issue":"5","key":"2195_CR10","doi-asserted-by":"publisher","first-page":"805","DOI":"10.2165\/00003495-199957050-00017","volume":"57","author":"CM Perry","year":"1999","unstructured":"Perry CM, Markham A. Piperacillin\/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs. 1999;57(5):805\u201343. https:\/\/doi.org\/10.2165\/00003495-199957050-00017.","journal-title":"Drugs"},{"issue":"7","key":"2195_CR11","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/cid\/cix034","volume":"64","author":"PD Tamma","year":"2017","unstructured":"Tamma PD, Rodriguez-Bano J. The Use of Noncarbapenem \u03b2-Lactams for the Treatment of Extended-Spectrum \u03b2-Lactamase Infections. Clin Infect Dis. 2017;64(7):972\u201380. https:\/\/doi.org\/10.1093\/cid\/cix034.","journal-title":"Clin Infect Dis"},{"issue":"Suppl A","key":"2195_CR12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/jac\/31.suppl_a.113","volume":"31","author":"O Kuye","year":"1993","unstructured":"Kuye O, Teal J, DeVries VG, et al. Safety profile of piperacillin\/tazobactam in phase I and III clinical studies. J Antimicrob Chemother. 1993;31(Suppl A):113\u201324. https:\/\/doi.org\/10.1093\/jac\/31.suppl_a.113.","journal-title":"J Antimicrob Chemother"},{"key":"2195_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12020240","author":"H Seo","year":"2023","unstructured":"Seo H, Kim E. Electrolyte disorders associated with piperacillin\/tazobactam: a pharmacovigilance study using the FAERS database. Antibiotics (Basel). 2023. https:\/\/doi.org\/10.3390\/antibiotics12020240.","journal-title":"Antibiotics (Basel)"},{"issue":"2","key":"2195_CR14","doi-asserted-by":"publisher","first-page":"e103408","DOI":"10.7759\/cureus.103408","volume":"18","author":"T Gogo-Peters","year":"2026","unstructured":"Gogo-Peters T, Nahuche MU, Okafor S. Clinical characteristics and predictors of hypokalemia in patients receiving piperacillin\/tazobactam: a retrospective observational audit. Cureus. 2026;18(2):e103408. https:\/\/doi.org\/10.7759\/cureus.103408.","journal-title":"Cureus"},{"key":"2195_CR15","unstructured":"Revision of \u201cprecautions\u201d for tazobactam piperacillin hydrate. Available: https:\/\/www.pmda.go.jp\/files\/000236937.pdf Accessed 18 Feb 2026."},{"issue":"8","key":"2195_CR16","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1001\/jama.2018.0438","volume":"319","author":"KS Kaye","year":"2018","unstructured":"Kaye KS, Bhowmick T, Metallidis S, et al. Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial. JAMA. 2018;319(8):788\u201399. https:\/\/doi.org\/10.1001\/jama.2018.0438.","journal-title":"JAMA"},{"issue":"12","key":"2195_CR17","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1093\/cid\/ciz181","volume":"69","author":"KS Kaye","year":"2019","unstructured":"Kaye KS, Rice LB, Dane AL, et al. Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, a phase 2\/3 randomized trial. Clin Infect Dis. 2019;69(12):2045\u201356. https:\/\/doi.org\/10.1093\/cid\/ciz181.","journal-title":"Clin Infect Dis"},{"key":"2195_CR18","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2025-004712","author":"K Uchida","year":"2025","unstructured":"Uchida K, Higashi K, Nakagawa Y, et al. Incidence of hypokalaemia in tazobactam\/piperacillin-treated patients and identification of risk factors: a retrospective observational study. Eur J Hosp Pharm. 2025. https:\/\/doi.org\/10.1136\/ejhpharm-2025-004712.","journal-title":"Eur J Hosp Pharm"},{"issue":"12","key":"2195_CR19","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1248\/yakushi.19-00143","volume":"139","author":"H Kuramoto","year":"2019","unstructured":"Kuramoto H, Masago S, Kashiwagi Y, et al. [Incidence and Risk Factors of Hypokalemia in Tazobactam\/Piperacillin-administered Patients]. Yakugaku Zasshi. 2019;139(12):1591\u2013600. https:\/\/doi.org\/10.1248\/yakushi.19-00143.","journal-title":"Yakugaku Zasshi"},{"issue":"8","key":"2195_CR20","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.3390\/antibiotics11081138","volume":"11","author":"H Seo","year":"2022","unstructured":"Seo H, Kim E. Incidence and determinants of piperacillin\/tazobactam-associated hypokalemia: a retrospective study. Antibiotics (Basel). 2022;11(8):1138. https:\/\/doi.org\/10.3390\/antibiotics11081138.","journal-title":"Antibiotics (Basel)"},{"issue":"5","key":"2195_CR21","doi-asserted-by":"publisher","first-page":"109708","DOI":"10.1016\/j.ejso.2025.109708","volume":"51","author":"Z Liu","year":"2025","unstructured":"Liu Z, Yang F, Hao Y, et al. A nomogram for predicting the risk of liver metastasis in non-functional neuroendocrine neoplasms: a population-based study. Eur J Surg Oncol. 2025;51(5):109708. https:\/\/doi.org\/10.1016\/j.ejso.2025.109708.","journal-title":"Eur J Surg Oncol"},{"key":"2195_CR22","doi-asserted-by":"publisher","first-page":"1621607","DOI":"10.3389\/fimmu.2025.1621607","volume":"16","author":"Q An","year":"2025","unstructured":"An Q, Wang H, Zhu H, et al. Nomogram-based risk stratification to analyze the value of receiving postoperative adjuvant therapy after neoadjuvant immunochemotherapy for patients with locally advanced esophageal squamous carcinoma. Front Immunol. 2025;16:1621607. https:\/\/doi.org\/10.3389\/fimmu.2025.1621607.","journal-title":"Front Immunol"},{"issue":"9","key":"2195_CR23","doi-asserted-by":"publisher","first-page":"e00634","DOI":"10.1128\/aac.00634-19","volume":"63","author":"M Gr\u00e9goire","year":"2019","unstructured":"Gr\u00e9goire M, Dailly E, Le Turnier P, et al. High-dose ceftriaxone for bacterial meningitis and optimization of administration scheme based on nomogram. Antimicrob Agents Chemother. 2019;63(9):e00634. https:\/\/doi.org\/10.1128\/aac.00634-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"2195_CR24","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.jiac.2019.11.009","volume":"26","author":"K Oda","year":"2020","unstructured":"Oda K, Katanoda T, Hashiguchi Y, et al. Development and evaluation of a vancomycin dosing nomogram to achieve the target area under the concentration-time curve. A retrospective study. J Infect Chemother. 2020;26(5):444\u201350. https:\/\/doi.org\/10.1016\/j.jiac.2019.11.009.","journal-title":"J Infect Chemother"},{"issue":"9","key":"2195_CR25","doi-asserted-by":"publisher","first-page":"e0291658","DOI":"10.1371\/journal.pone.0291658","volume":"18","author":"H Bai","year":"2023","unstructured":"Bai H, Li H, Nie X, et al. Development and validation of a nomogram for predicting cefoperazone\/sulbactam-induced hypoprothrombinaemia in Hospitalized adult patients. PLoS ONE. 2023;18(9):e0291658. https:\/\/doi.org\/10.1371\/journal.pone.0291658.","journal-title":"PLoS ONE"},{"issue":"2","key":"2195_CR26","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239\u201345. https:\/\/doi.org\/10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"2195_CR27","doi-asserted-by":"publisher","first-page":"432","DOI":"10.23736\/s0375-9393.21.15129-6","volume":"87","author":"F Corradi","year":"2021","unstructured":"Corradi F, Isirdi A, Malacarne P, et al. Low diaphragm muscle mass predicts adverse outcome in patients hospitalized for COVID-19 pneumonia: an exploratory pilot study. Minerva Anestesiol. 2021;87(4):432\u20138. https:\/\/doi.org\/10.23736\/s0375-9393.21.15129-6.","journal-title":"Minerva Anestesiol"},{"issue":"6","key":"2195_CR28","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1093\/jac\/dkn117","volume":"61","author":"EJ Hoorn","year":"2008","unstructured":"Hoorn EJ, Zietse R. Severe hypokalaemia caused by flucloxacillin. J Antimicrob Chemother. 2008;61(6):1396\u20138. https:\/\/doi.org\/10.1093\/jac\/dkn117.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2195_CR29","doi-asserted-by":"publisher","first-page":"123","DOI":"10.5527\/wjn.v1.i5.123","volume":"1","author":"CG Musso","year":"2012","unstructured":"Musso CG, Alvarez Gregori J, Jauregui JR, et al. Creatinine, urea, uric acid, water and electrolytes renal handling in the healthy oldest old. World J Nephrol. 2012;1(5):123\u20136. https:\/\/doi.org\/10.5527\/wjn.v1.i5.123.","journal-title":"World J Nephrol"},{"issue":"9","key":"2195_CR30","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2165\/00044011-200424090-00004","volume":"24","author":"G Passare","year":"2004","unstructured":"Passare G, Viitanen M, T\u00f6rring O, et al. Sodium and potassium disturbances in the elderly\u202f: prevalence and association with drug use. Clin Drug Investig. 2004;24(9):535\u201344. https:\/\/doi.org\/10.2165\/00044011-200424090-00004.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"2195_CR31","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11255-004-2361-4","volume":"37","author":"CG Musso","year":"2005","unstructured":"Musso CG, Miguel R, Algranati L, et al. Renal potassium excretion: comparison between chronic renal disease patients and old people. Int Urol Nephrol. 2005;37(1):167\u201370. https:\/\/doi.org\/10.1007\/s11255-004-2361-4.","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"2195_CR32","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1093\/ageing\/afq034","volume":"39","author":"AJ Cruz-Jentoft","year":"2010","unstructured":"Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: european consensus on definition and diagnosis: Report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412\u201323. https:\/\/doi.org\/10.1093\/ageing\/afq034.","journal-title":"Age Ageing"},{"issue":"2","key":"2195_CR33","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/0016-5085(94)90184-8","volume":"107","author":"R Agarwal","year":"1994","unstructured":"Agarwal R, Afzalpurkar R, Fordtran JS. Pathophysiology of potassium absorption and secretion by the human intestine. Gastroenterology. 1994;107(2):548\u201371. https:\/\/doi.org\/10.1016\/0016-5085(94)90184-8.","journal-title":"Gastroenterology"},{"issue":"1","key":"2195_CR34","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.arth.2023.07.018","volume":"39","author":"ZA McConnell","year":"2024","unstructured":"McConnell ZA, Patel KM, Mears SC, et al. Systemic inflammatory response syndrome and prosthetic joint infection. J Arthroplasty. 2024;39(1):236\u201341. https:\/\/doi.org\/10.1016\/j.arth.2023.07.018.","journal-title":"J Arthroplasty"},{"issue":"4","key":"2195_CR35","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/j.ecl.2006.09.013","volume":"35","author":"P Schuetz","year":"2006","unstructured":"Schuetz P, M\u00fcller B. The hypothalamic-pituitary-adrenal axis in critical illness. Endocrinol Metab Clin North Am. 2006;35(4):823\u201338. https:\/\/doi.org\/10.1016\/j.ecl.2006.09.013.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"2195_CR36","doi-asserted-by":"publisher","first-page":"609","DOI":"10.4103\/0253-7613.84986","volume":"43","author":"SA Zaki","year":"2011","unstructured":"Zaki SA, Lad V. Piperacillin-tazobactam-induced hypokalemia and metabolic alkalosis. Indian J Pharmacol. 2011;43(5):609\u201310. https:\/\/doi.org\/10.4103\/0253-7613.84986.","journal-title":"Indian J Pharmacol"},{"issue":"5630","key":"2195_CR37","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1136\/bmj.4.5630.550","volume":"4","author":"FP Brunner","year":"1968","unstructured":"Brunner FP, Frick PG. Hypokalaemia, metabolic alkalosis, and hypernatraemia due to \u201cmassive\u201d sodium penicillin therapy. Br Med J. 1968;4(5630):550\u20132. https:\/\/doi.org\/10.1136\/bmj.4.5630.550.","journal-title":"Br Med J"},{"issue":"5","key":"2195_CR38","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1128\/aac.03122-15","volume":"60","author":"JA Viehman","year":"2016","unstructured":"Viehman JA, Oleksiuk LM, Sheridan KR, et al. Adverse events lead to drug discontinuation more commonly among patients who receive nafcillin than among those who receive oxacillin. Antimicrob Agents Chemother. 2016;60(5):3090\u20135. https:\/\/doi.org\/10.1128\/aac.03122-15.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"2195_CR39","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1111\/bcp.13969","volume":"85","author":"C van der Heijden","year":"2019","unstructured":"van der Heijden C, Duizer ML, Fleuren H, et al. Intravenous flucloxacillin treatment is associated with a high incidence of hypokalaemia. Br J Clin Pharmacol. 2019;85(12):2886\u201390. https:\/\/doi.org\/10.1111\/bcp.13969.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2195_CR40","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1472-8206.2010.00859.x","volume":"24","author":"T Clausen","year":"2010","unstructured":"Clausen T. Hormonal and pharmacological modification of plasma potassium homeostasis. Fundam Clin Pharmacol. 2010;24(5):595\u2013605. https:\/\/doi.org\/10.1111\/j.1472-8206.2010.00859.x.","journal-title":"Fundam Clin Pharmacol"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02195-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-026-02195-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-026-02195-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:58:46Z","timestamp":1789117126000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-026-02195-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,24]]},"references-count":40,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["2195"],"URL":"https:\/\/doi.org\/10.1007\/s11096-026-02195-z","relation":{},"ISSN":["2210-7711"],"issn-type":[{"value":"2210-7711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,24]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Xi\u2019an Central Hospital (No. LW-2025\u2013011). Due to its retrospective design and the use of fully anonymised patient data from electronic medical records without direct intervention, the committee waived the requirement for informed patient consent.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}